![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Broadcom
AVGO
Taiwan Semiconductor
TSM
Tesla
TSLA
ASML Holding
ASML
Qualcomm
QCOM
US Stock MarketDetailed Quotes
BIOA BioAge Labs
- 4.280
- -0.310-6.75%
Close Dec 13 16:00 ET
- 4.300
- +0.020+0.46%
Post 19:52 ET
153.43MMarket Cap-2.06P/E (TTM)
4.788High4.240Low660.67KVolume4.660Open4.590Pre Close2.93MTurnover6.29%Turnover RatioLossP/E (Static)35.85MShares26.62052wk High0.49P/B44.94MFloat Cap4.23052wk Low--Dividend TTM10.50MShs Float26.620Historical High--Div YieldTTM11.95%Amplitude4.230Historical Low4.439Avg Price1Lot Size
BioAge Labs Stock Forum
Sign in to post a comment
1
8
3
$BioAge Labs (BIOA.US)$ fight to establish the bottom!!!
2
$BioAge Labs (BIOA.US)$ They have other drugs in the pipeline. It just recently debuted. And it went sideways pretty much the last two months. 2.3 million short shares also that are near cost to be covered. Maybe over reaction. Should see a recovery to 10.00 at least.
9
5
$BioAge Labs (BIOA.US)$ historical low…wonder where they go from here…
3
$BioAge Labs (BIOA.US)$ I got burned in RLMD, no overreaction play but declined more, so it might be another RLMD which I too scared to touch.
4
$BioAge Labs (BIOA.US)$
BioAge Labs Discontinues STRIDES Phase 2 Trial Of Azelaprag For Obesity Following Liver Transaminitis Observations; Plans To Evaluate Data And Provide Updates On Azelaprag In Q1 2025 While Advancing NLRP3 Inhibitor Program With IND Submission Expected.
BioAge Labs (BIOA) has announced the discontinuation of its STRIDES Phase 2 clinical trial evaluating azelaprag in combination with tirzepatide for obesity treatment. The decision follows observations of liver transamini...
BioAge Labs Discontinues STRIDES Phase 2 Trial Of Azelaprag For Obesity Following Liver Transaminitis Observations; Plans To Evaluate Data And Provide Updates On Azelaprag In Q1 2025 While Advancing NLRP3 Inhibitor Program With IND Submission Expected.
BioAge Labs (BIOA) has announced the discontinuation of its STRIDES Phase 2 clinical trial evaluating azelaprag in combination with tirzepatide for obesity treatment. The decision follows observations of liver transamini...
No comment yet
Trending US Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Strik57 : I believe way oversold,clinical trails are testing new drugs n if issue stop trails.more to them then just one they stop because safety issues so added some to my portfolio again today![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
Green-Day OP Strik57 : Nice!
I also like that this company has integrity!
TheLongKhan : guess we're in it for the long haul
Green-Day OP TheLongKhan : Maybe don’t have to wait very long![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
103753999 : Time to buy
View more comments...